Aspirations For and the Current Status of Blood-based Cancer Diagnostics
Walter Koch, Vice President, Roche Molecular Systems
Dozens of published research studies have reported that quantitative
analysis of somatic mutations in blood is associated with dynamic
responses of tumors to therapy, development of drug resistance during
therapy and relapse after treatment, as well as genomic evolution of
primary tumors and metastases. To date, only one “liquid biopsy” test
has gained FDA approval; the cobas® EGFR Mutation Test v2 is used to
genotype NSCLC for dozens of EGFR activating and resistance mutations
used for selection of tyrosine kinase inhibitors Erlotinib or
Osimertinib. Beyond genotyping tumors for therapy selection or clinical
trial enrollment, there is an unmet medical need for better noninvasive
biomarkers to monitor solid tumor therapy response, recurrence, and
residual disease after surgical removal of early stage tumors. This
talk will explore the clinical development needed for liquid biopsy
tests to be broadly included in cancer diagnosis and treatment
guidelines, and to be used in routine clinical care with reimbursement.
|
|